Seaport Therapeutics Presents Latest Data from Phase 1 Study of SPT-300
BOSTON-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company, has announced notable developments regarding its Founded Entity, Seaport Therapeutics. The company recently presented additional data from its innovative SPT-300 study during the American College of Neuropsychopharmacology (ACNP) Annual Meeting. This meeting serves as a prestigious platform for experts in neuropsychopharmacology to share advancements and insights in their fields.
Understanding SPT-300
SPT-300 is an oral prodrug of allopregnanolone, an endogenous neurosteroid. This compound has shown potential as a rapid antidepressant with anxiolytic (anxiety-reducing) effects validated by third-party trials. During the recent Phase 1 study, which included healthy volunteers, researchers sought to evaluate the drug's safety, tolerability, pharmacokinetics, and its effect on GABAA receptors, known for their role in reducing neuronal excitability throughout the nervous system.
Highlights from the Phase 1 Study
The Phase 1 trial encompassed 99 participants and involved several crucial evaluations: double-blind single ascending dose, multiple ascending dose, and open-label food effect assessments. These comprehensive analyses allowed the team to gather significant data regarding SPT-300's effects on oral bioavailability and overall safety. The results confirmed that SPT-300 was predominantly well-tolerated, with adverse events being mild to moderate, transient, and dose-dependent.
Among the notable adverse events reported, somnolence was the most common, illustrating that while SPT-300 has pharmacodynamic activity, monitoring is an essential component of its use. Importantly, the therapeutic levels achieved with SPT-300 were up to approximately nine times higher than those linked with the traditional allopregnanolone treatment, which has shown limited bioavailability.
Implications for the Future
The data presented emphasizes SPT-300's suitability for chronic dosing, particularly in a placebo-controlled Phase 2b study focused on major depressive disorder. The Phase 1 study revealed increased EEG beta frequency power and reduced saccadic eye velocity, showcasing the compound's potential efficacy. It was also observed that somnolence, the prominent side effect, peaked around 4 hours following dosing, lending insight into its pharmacodynamics and guiding future treatment protocols.
Expert Insights on SPT-300 Developments
Dr. Tony Loebel, Chief Medical Officer and President of Clinical Development at Seaport Therapeutics, expressed optimism regarding the findings. He remarked on the well-tolerated nature of SPT-300 and its rapid acting pharmacodynamic effects, highlighting the demand for innovative neuropsychiatric solutions. Dr. Loebel emphasized that the oral form of allopregnanolone can provide significant advantages for patients requiring ongoing management of depressive and anxious symptoms.
About Seaport Therapeutics
Seaport Therapeutics operates in a space that is crucial for advancing neuropsychiatric treatments to meet high unmet needs. The company is known for leveraging its proprietary Glyph technology platform, which enables oral bioavailability and minimizes side effects often associated with traditional delivery methods. By fostering a pipeline rich in potential first and best-in-class therapies, Seaport is poised to impact the treatment landscape for patients suffering from various neuropsychiatric conditions.
About PureTech Health
PureTech Health is dedicated to revolutionizing medicine to help those afflicted by severe diseases. Their robust research and development initiatives are supported by a widespread network of professionals across various sectors within science and healthcare. This synergy has led to the establishment of 29 therapeutic programs, three of which have received approval from the U.S. Food and Drug Administration. PureTech's commitment to innovative solutions continues to drive forward the clinical development of its therapeutics, either independently or through its Founded Entities.
Frequently Asked Questions
What is SPT-300?
SPT-300 is an oral prodrug of allopregnanolone, designed to function as a rapidly acting antidepressant with potential anxiolytic effects.
How did the Phase 1 study evaluate SPT-300?
The Phase 1 study assessed SPT-300's safety, tolerability, pharmacokinetics, and its engagement with GABAA receptors in healthy volunteers.
What were the notable side effects observed in the study?
The primary side effect noted was somnolence, which was mild, transient, and dose-dependent in nature.
What are the next steps for SPT-300 development?
Following the positive Phase 1 data, a Phase 2b placebo-controlled study is planned to delve deeper into its efficacy for treating major depressive disorder.
What is the significance of PureTech Health’s role in this development?
PureTech Health provides essential support and infrastructure for Seaport Therapeutics, facilitating the development of new therapeutic candidates like SPT-300.
